KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS GENES IN SERONEGATIVE SPONDYLOARTHROPATHIES
Corresponding author:
[email protected]
Accepted
28 March 2026
Available Online
15 March 2016
Abstract
THE SERONEGATIVE SPONDYLOARTHROPATHIES (SPA) ARE INFLAMMATORY RHEUMATIC DISEASES WITH COMMON CLINICAL FEATURES AND GENETIC SIMILARITIES NOT LIMITED ONLY TO HLA -B27. SEVERAL STUDIES SUGGESTED THAT KILLER CELL IMMUNOLOGLOBULIN -LIKE RECEPTORS (KIR) GENES ARE ONE OF THE NON-MHC GENES ASSOCIATED WITH SPA, ALONG WITH ERAP1 AND IL23R. KIR GENES ENCODE REGULATING RECEPTORS WITH ACTIVATING OR INHIBITORY FUNCTION WHICH ARE EXPRESSED BY NATURAL KILLER CELLS (NK) AND SOME OF T LYMPHOCYTES. KIR MOLECULES RECOGNIZE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I MOLECULES, MORE PRECISELY, DISTINCT SUBSETS OF HLA-A, HLA-B, HLA-C AND HLA-G ALLOTYPES, MODULATING THE REACTIVITY OF THE NK CELL. AN IMBALANCE BETWEEN ACTIVATING AND INHIBITORY KIR ALLELES KIR3DS1 AND KIR3DL1 IN THE PRESENCE OF CERTAIN HLA-B27 ALLELES (B*2705) MAY CONTRIBUTE TO ANKYLOSING SPONDYLITIS (AS) PATHOGENESIS. THE RISK OF PSORIATIC ARTHRITIS (PSA) IS INCREASED IN SUBJECTS WITH ACTIVATING KIR2DS1 AND/OR KIR2DS2 GENES PRESENT. THIS ARTICLE UNDERLINES THE IMPORTANCE OF KIR GENES AND THEIR COMPLEX RELATION WITH THEIR LIGANDS, ESPECIALLY WITH HLA -B27. THIS UNIQUE ENCOUNTER MAY BE DECISIVE FOR THE IMMUNO-INFLAMMATORY RESPONSE SEEN IN AS/SPA.
Keywords
KILLER CELL IMMUNOLOGLOBULIN -LIKE RECEPTORS (KIR)
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, J. D. Lifson, T. M. Allen, M. Carrington, and M. Altfeld. 2007. "Differential natural killer cell -mediated inhibition of HIV -1 re plication based on distinct KIR/HLA subtypes." J Exp Med no. 204 (12):3027-36. doi: 10.1084/jem.20070695.
[2]
Arlettaz, L., S. Degermann, C. De Rham, E. Roosnek, and B. Huard. 2004. "Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity." Eur J Immunol no. 34 (12):3413-22. doi: 10.1002/eji.200324756.
[3]
Biassoni, R., C. Cantoni, D. Pende, S. Sivori, S. Parolini, M. Vitale, C. Bottino, and A. Moretta. 2001. "Human natural killer cell receptors and co-receptors." Immunol Rev no. 181:203-14.
[4]
Bowness, P., A. Ridley, J. Shaw, A. T. Chan, I. Wong-Baeza, M. Fleming, F. Cummings, A. McMichael, and S. Kollnberger. 2011. "Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis." J Immunol no. 186 (4):2672-80. doi: 10.4049/jimmunol.1002653.
[5]
Boyington, J. C., and P. D. Sun. 2002. "A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors." Mol Immunol no. 38 (14):1007-21.
[6]
Braun, J., and J. Sieper. 2010. "[Spondyloarthritides]." Z Rheumatol no. 69 (5):425-32.
[7]
Breban, M., F. Costantino, C. Andre, G. Chiocchia, and H. J. Garchon. 2015. "Revisiting MHC genes in spondyloarthritis." Curr Rheumatol Rep no. 17 (6):516. doi: 10.1007/s11926 -015-0516-1.
[8]
Brewerton, D. A., F. D. Hart, A. Nicholls, M. Caffrey, D. C. James, and R. D. Sturrock. 1973. "Ankylosing spondylitis and HL-A 27." Lancet no. 1 (7809):904-7.
[9]
Brown, M. A. 2009. "Genetics and the pathogenesis of ankylosing spondylitis." Curr Opin Rheu matol no. 21 (4):318-23.
[10]
Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. "Activation, coactivation, and costimulation of resting human natural killer cells." Immunol Rev no. 214:73 -91. doi: 10.1111/j.1600 - 065X.2006.00457.x.
[11]
Caffrey, M. F., and D. C. James. 1973. "Human lymphocyte antigen association in ankylosing spondylitis." Nature no. 242 (5393):121.
[12]
Caligiuri, Michael A. 2008. "Human natural killer cells." Blood no. 112 (3):461 -469. doi: 10.1182/blood - 2007-09-077438.
[13]
Campbell, Kerry S., and Amanda K. Purdy. 2011. "Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations." Immunology no. 132 (3):315-325. doi: 10.1111/j.1365-2567.2010.03398.x.
[14]
Carr, W. H., D. B. Rosen, H. Arase, D. F. Nixon, J. Michaelsson, and L. L. Lanier. 2007. "Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12 -associated receptor expressed on NK cells that triggers NK cell activation." J Immunol no. 178 (2):647-51.
[15]
Carter, K. W., A. Pluzhnikov, A. E. Timms, C. Miceli -Richard, C. Bourgain, B. P. Wordsworth, H. Jean-Pierre, N. J. Cox, L. J. Palmer, M. Breban, J. D. Reveille, and M. A. Brown. 2007. "Combined analysis of three w hole genome linkage scans for Ankylosing Spondylitis." Rheumatology (Oxford) no. 46 (5):763-71. doi: 10.1093/rheumatology/kel443.
[16]
Cauli, A., M. Piga, G. Dessole, G. Porru, A. Floris, A. Vacca, E. Desogus, G. La Nasa, and A. Mathieu. 2014. "Killer -cell immu noglobulin-like receptors (KIR) and HLA -class I heavy chains in ankylosing spondylitis." Drug Dev Res no. 75 Suppl 1:S15-9. doi: 10.1002/ddr.21187.
[17]
Chaix, J., M. S. Tessmer, K. Hoebe, N. Fuseri, B. Ryffel, M. Dalod, L. Alexopoulou, B. Beutler, L. Brossay, E. Vivier, and T. Walzer. 2008. "Cutting edge: Priming of NK cells by IL-18." J Immunol no. 181 (3):1627-31.
[18]
Chan, A. T., S. D. Kollnberger, L. R. Wedderburn, and P. Bowness. 2005. "Expansion and enhanced survival of natural killer cells expressing the kil ler immunoglobulin -like receptor KIR3DL2 in spondylarthritis." Arthritis Rheum no. 52 (11):3586-95. doi: 10.1002/art.21395. Research and Science Today No. 1(11)/2016
[19]
Chandran, V., S. B. Bull, F. J. Pellett, R. Ayearst, R. A. Pollock, and D. D. Gladman. 2014. "Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis." Rheumatology (Oxford) no. 53 (2):233-9. doi: 10.1093/rheumatology/ket296.
[20]
Colbert, R. A., M. L. DeLay, E. I. Klenk, and G. Layh -Schmitt. 2010. "From HLA -B27 to spondyloarthritis: a journey t hrough the ER." Immunol Rev no. 233 (1):181 -202. doi: 10.1111/j.0105 - 2896.2009.00865.x.
[21]
Deng, Z., J. Zhen, B. Zhu, G. Zhang, Q. Yu, D. Wang, Y. Xu, L. He, and L. Lu. 2015. "Allelic diversity of KIR3DL1/3DS1 in a southern Chinese population." Hum Immunol no . 76 (9):663 -6. doi: 10.1016/j.humimm.2015.09.017.
[22]
Diaz-Pena, R., M. A. Blanco -Gelaz, and C. Lopez -Larrea. 2009. "KIR genes and their role in spondyloarthropathies." Adv Exp Med Biol no. 649:286-99.
[23]
Diaz-Pena, R., M. A. Blanco -Gelaz, B. Suarez -Alvarez, J. Martinez-Borra, A. Lopez -Vazquez, R. Alonso-Arias, J. Bruges -Armas, J. R. Vidal -Castineira, and C. Lopez -Larrea. 2008. "Activating KIR genes are associated with ankylosing spondylitis in Asian populations." Hum Immunol no. 69 (7):437 -42. doi: 10.1016/j.humimm.2008.04.012.
[24]
Diaz-Pena, R., J. R. Vidal-Castineira, R. Alonso-Arias, B. Suarez-Alvarez, J. L. Vicario, R. Solana, E. Collantes, A. Lopez -Vazquez, J. Martinez -Borra, and C. Lopez -Larrea. 2010. "Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis." Arthritis Rheum no. 62 (4):1000-6. doi: 10.1002/art.27332.
[25]
Diaz-Pena, R., J. R. Vidal -Castineira, J. Mulero, A. Sanchez, R. Queiro, and C. Lopez -Larrea. 2015. "Activating killer immunoglobulin -like receptors gene s are associated with increased susceptibility to ankylosing spondylitis." Clin Exp Immunol no. 180 (2):201-6. doi: 10.1111/cei.12568.
[26]
Falco, M., L. Moretta, A. Moretta, and C. Bottino. 2013. "KIR and KIR ligand polymorphism: a new area for clinical applications?" Tissue Antigens no. 82 (6):363-73. doi: 10.1111/tan.12262.
[27]
Gomez-Lozano, N., C. M. Gardiner, P. Parham, and C. Vilches. 2002. "Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B." Immunogenetics no. 54 (5):314 -9. doi: 10.1007/s00251-002-0476-2.
[28]
Gonzalez-Galarza, F. F., S. Christmas, D. Middleton, and A. R. Jones. 2011. "Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations." Nucleic Acids Res no. 39 (Database issue):D913-9. doi: 10.1093/nar/gkq1128.
[29]
Gonzalez-Galarza, F. F., L. Y. Takeshita, E. J. Santos, F. Kempson, M. H. Maia, A. L. da Silva, A. L. Teles e Silva, G. S. Ghattaoraya, A. Alfirevic, A. R. Jones, and D. Middleton. 2015. "Allele frequency net 2015 update: new f eatures for HLA epitopes, KIR and disease and HLA adverse drug reaction associations." Nucleic Acids Res no. 43 (Database issue):D784 -8. doi: 10.1093/nar/gku1166.
[30]
Guia, S., C. Cognet, L. de Beaucoudrey, M. S. Tessmer, E. Jouanguy, C. Berger, O. Filipe -Santos, J. Feinberg, Y. Camcioglu, J. Levy, S. Al Jumaah, S. Al -Hajjar, J. L. Stephan, C. Fieschi, L. Abel, L. Brossay, J. L. Casanova, and E. Vivier. 2008. "A role for interleukin -12/23 in the maturation of human natural killer and CD56+ T cells in vivo." Blood no. 111 (10):5008-16. doi: 10.1182/blood-2007-11-122259.
[31]
Harvey, D., J. J. Pointon, C. Sleator, A. Meenagh, C. Farrar, J. Y. Sun, D. Senitzer, D. Middleton, M. A. Brown, and B. P. Wordsworth. 2009. "Analysis of killer immunoglobulin -like receptor genes in ankylosing spondylitis." Ann Rheum Dis no. 68 (4):595-8. doi: 10.1136/ard.2008.095927.
[32]
Herberman, R. B., M. E. Nunn, and D. H. Lavrin. 1975. "Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity." Int J Cancer no. 16 (2):216-29.
[33]
Jiao, Y. L., C. Y. Ma, L. C. Wang, B. Cui, J. Zhang, L. You, Z. J. Chen, J. F. Li, and Y. R. Zhao. 2008. "Polymorphisms of KIRs gene and HLA -C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease." J Clin Immunol no. 28 (4):343 -9. doi: 10.1007/s10875 -008- 9183-6.
[34]
Jiao, Y. L., B. C. Zhang, L. You, J. F. Li, J. Zhang, C. Y. Ma, B. Cui, L. C. Wang, Z. J. Chen, and Y. R. Zhao. 2010. "Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis." J Clin Immunol no. 30 (6):840 -4. doi: 10.1007/s10875-010-9444-z.
[35]
Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. "Selective rejection of H -2-deficient lymphoma variants suggests alternative immune defence strategy." Nature no. 319 (6055):675 -8. doi: 10.1038/319675a0. March 2016
[36]
Kiessling, R., E. Klein, and H. Wigzell. 1975. ""Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype." Eur J Immunol no. 5 (2):112-7. doi: 10.1002/eji.1830050208.
[37]
Kollnberger, S., L. Bird, M. Y. Sun, C. Retiere, V. M. Braud, A. McMichael, and P. Bo wness. 2002. "Cell-surface expression and immune receptor recognition of HLA -B27 homodimers." Arthritis Rheum no. 46 (11):2972-82. doi: 10.1002/art.10605.
[38]
Kollnberger, S., A. Chan, M. Y. Sun, L. Y. Chen, C. Wright, K. di Gleria, A. McMichael, and P. Bowness. 2007. "Interaction of HLA -B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA -B27 heterotrimers, is independent of the sequence of bound peptide." Eur J Immunol no. 37 (5):1313 -22. doi: 10.1002/eji.200635997.
[39]
Korendowych, E., and N. McHugh. 2005. "Genetic factors in psoriatic arthritis." Curr Rheumatol Rep no. 7 (4):306-12.
[40]
Landewe, R. B., and D. M. van der Heijde. 2011. "[The recognition of patients with spondyloarthritis. New classification criteria]." Ned Tijdschr Geneeskd no. 155 (30-31).
[41]
Lanier, L. L. 2005. "NK cell recognition." Annu Rev Immunol no. 23:225 -74. doi: 10.1146/annurev.immunol.23.021704.115526.
[42]
Laval, S. H., A. Timms, S. Edwards, L. Bradbury, S. Brophy, A. Milicic, L. Rubin, K. A. Siminovitch, D. E. Weeks, A. Calin, B. P. Word sworth, and M. A. Brown. 2001. "Whole -genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci." Am J Hum Genet no. 68 (4):918-
[26]
doi: 10.1086/319509.
[43]
Levinson, R. D., T. M. Martin, L. Luo, E. Ashouri, J. T. Rosenbaum, J . R. Smith, C. R. Austin, J. R. Lutt, and R. Rajalingam. 2010. "Killer cell immunoglobulin -like receptors in HLA -B27-associated acute anterior uveitis, with and without axial spondyloarthropathy." Invest Ophthalmol Vis Sci no. 51 (3):1505-10. doi: 10.1167/iovs.09-4232.
[44]
Ljunggren, H. G., and K. Karre. 1990. "In search of the 'missing self': MHC molecules and NK cell recognition." Immunol Today no. 11 (7):237-44.
[45]
Lodoen, M. B., and L. L. Lanier. 2005. "Viral modulation of NK cell immunity." Nat Rev Microbiol no. 3 (1):59-69. doi: 10.1038/nrmicro1066.
[46]
Lopez-Larrea, C., M. A. Blanco -Gelaz, J. C. Torre -Alonso, J. Bruges Armas, B. Suarez -Alvarez, L. Pruneda, A. R. Couto, S. Gonzalez, A. Lopez -Vazquez, and J. Martinez -Borra. 2006. "Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations." Arthritis Res Ther no. 8 (4):R101. doi: 10.1186/ar1988.
[47]
Lucas, M., W. Schachterle, K. Oberle, P. Aichele, and A. Diefenbach. 2007. "Dendritic cells prime natural killer cells by t rans-presenting interleukin 15." Immunity no. 26 (4):503 -17. doi: 10.1016/j.immuni.2007.03.006.
[48]
Mahfouz, R. A., A. S. Sabbagh, W. Shamseddine, A. Bazarbachi, G. Ibrahim, T. Arayssi, N. El Hajj, R. Rayes, G. S. Zaatari, G. Khazen, and R. A. Khalaf. 2009. "Distribution of killer cell immunoglobulin- like receptor (KIR) genotypes in patients with familial Mediterranean fever." Genet Test Mol Biomarkers no. 13 (1):91-5. doi: 10.1089/gtmb.2008.0081.
[49]
Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T. I. Arnon, Y. B ushkin, D. M. Davis, J. L. Strominger, J. W. Yewdell, and A. Porgador. 2001. "Recognition of haemagglutinins on virus -infected cells by NKp46 activates lysis by human NK cells." Nature no. 409 (6823):1055-60. doi: 10.1038/35059110.
[50]
Marsh, S. G., P. Parham, B. Dupont, D. E. Geraghty, J. Trowsdale, D. Middleton, C. Vilches, M. Carrington, C. Witt, L. A. Guethlein, H. Shilling, C. A. Garcia, K. C. Hsu, and H. Wain. 2003a. "Killer- cell immunoglobulin-like receptor (KIR) nomenclature report, 2002." Immunogenetics no. 55 (4):220-6. doi: 10.1007/s00251-003-0571-z.
[51]
Marsh, S. G., P. Parham, B. Dupont, D. E. Geraghty, J. Trowsdale, D. Middleton, C. Vilches, M. Carrington, C. Witt, L. A. Guethlein, H. Shilling, C. A. Garcia, K. C. Hsu, and H. Wain. 2003b. "Killer- cell immunoglobulin-like receptor (KIR) nomenclature report, 2002." Hum Immunol no. 64 (6):648 -54.
[52]
Martin, M. P., G. Nelson, J. H. Lee, F. Pellett, X. Gao, J. Wade, M. J. Wilson, J. Trowsdale, D. Gladman, and M. Carrington. 2002. "Cutting edge: susceptibility t o psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles." J Immunol no. 169 (6):2818- 22.
[53]
Middleton, D., F. Williams, and I. A. Halfpenny. 2005. "KIR genes." Transpl Immunol no. 14 (3 -4):135-
[42]
doi: 10.1016/j.trim.2005.03.002. Research and Science Today No. 1(11)/2016
[54]
Middleton, Derek, and Faviel Gonzelez. 2010. "The extensive polymorphism of KIR genes." Immunology no. 129 (1):8-19. doi: 10.1111/j.1365-2567.2009.03208.x.
[55]
Moesta, A. K., P. J. Norman, M. Yawata, N. Yawata, M. Gleimer, and P. Parham. 2008. "Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA- C than KIR2DL3." J Immunol no. 180 (6):3969-79.
[56]
Moon, S. J., E. J. Oh, Y. Kim, K. S. Kim, S. K. Kwok, J. H. Ju, K. S. Pa rk, H. Y. Kim, and S. H. Park. 2013. "Diversity of killer cell immunoglobulin -like receptor genes in uveitis associated with autoimmune diseases: ankylosing spondylitis and Behcet disease." Ocul Immunol Inflamm no. 21 (2):135 -43. doi: 10.3109/09273948.2012.754905.
[57]
O'Connor, G. M., K. J. Guinan, R. T. Cunningham, D. Middleton, P. Parham, and C. M. Gardiner. 2007. "Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells." J Immunol no. 178 (1):235-41.
[58]
O'Connor, Geraldine M., Orla M. Hart, and Cla ir M. Gardiner. 2006. "Putting the natural killer cell in its place." Immunology no. 117 (1):1-10. doi: 10.1111/j.1365-2567.2005.02256.x.
[59]
Ortaldo, J. R., R. T. Winkler-Pickett, S. Nagata, and C. F. Ware. 1997. "Fas involvement in human NK cell apoptosis: lack of a requirement for CD16-mediated events." J Leukoc Biol no. 61 (2):209-15.
[60]
Rajagopalan, S., J. Fu, and E. O. Long. 2001. "Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig -like receptor KIR2DL4 (CD158d) in res ting NK cells." J Immunol no. 167 (4):1877-81.
[61]
Raulet, D. H., S. Gasser, B. G. Gowen, W. Deng, and H. Jung. 2013. "Regulation of ligands for the NKG2D activating receptor." Annu Rev Immunol no. 31:413 -41. doi: 10.1146/annurev -immunol-032712- 095951.
[62]
Robinson, J., J. A. Halliwell, H. McWilliam, R. Lopez, and S. G. Marsh. 2013. "IPD --the Immuno Polymorphism Database." Nucleic Acids Res no. 41 (Database issue):D1234 -40. doi: 10.1093/nar/gks1140.
[63]
Robinson, James, Matthew J. Waller, Peter Stoehr, and Steven G. E. Marsh. 2005. "IPD—the Immuno Polymorphism Database." Nucleic Acids Research no. 33 (suppl 1):D523 -D526. doi: 10.1093/nar/gki032.
[64]
Rosenberg, E. B., R. B. Herberman, P. H. Levine, R. H. Halterman, J. L. McCoy, and J. R. Wunderlich. 1972. "Lymphocyte cytotox icity reactions to leukemia -associated antigens in identical twins." Int J Cancer no. 9 (3):648-58.
[65]
Schlosstein, L., P. I. Terasaki, R. Bluestone, and C. M. Pearson. 1973. "High association of an HL -A antigen, W27, with ankylosing spondylitis." N Engl J Me d no. 288 (14):704 -6. doi: 10.1056/nejm197304052881403.
[66]
Sharma, D., K. Bastard, L. A. Guethlein, P. J. Norman, N. Yawata, M. Yawata, M. Pando, H. Thananchai, T. Dong, S. Rowland -Jones, F. M. Brodsky, and P. Parham. 2009. "Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA -A*2402." J Immunol no. 183 (7):4569-82. doi: 10.4049/jimmunol.0901734.
[67]
Shegarfi, Hamid, Fatemeh Naddafi, and Abbas Mirshafiey. 2012. "Natural Killer Cells and Their Role in Rheumatoid Arthritis: Friend or Foe?" The Scientific World Journal no. 2012:491974. doi: 10.1100/2012/491974.
[68]
Sivori, S., M. Falco, S. Carlomagno, E. Romeo, C. Soldani, A. Bensussan, A. Viola, L. Moretta, and A. Moretta. 2010. "A novel KIR -associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2." Blood no. 116 (10):1637-47. doi: 10.1182/blood-2009-12-256586.
[69]
Smith, H. R., J. W. Heusel, I. K. Mehta, S. Kim, B. G. Dorner, O. V. Naidenko, K. Iizuka, H. Furukawa, D. L. Beckman, J. T. Pingel, A. A. Scalzo, D. H. Fremont, and W. M. Yokoyama. 2002. "Recognition of a virus -encoded ligand by a natur al killer cell activation receptor." Proc Natl Acad Sci U S A no. 99 (13):8826-31. doi: 10.1073/pnas.092258599.
[70]
Stewart-Jones, G. B., K. di Gleria, S. Kollnberger, A. J. McMichael, E. Y. Jones, and P. Bowness. 2005. "Crystal structures and KIR3DL1 recognit ion of three immunodominant viral peptides complexed to HLA - B*2705." Eur J Immunol no. 35 (2):341-51. doi: 10.1002/eji.200425724.
[71]
Stewart, C. A., F. Laugier -Anfossi, F. Vely, X. Saulquin, J. Riedmuller, A. Tisserant, L. Gauthier, F. Romagne, G. Ferracci, F. A. Arosa, A. Moretta, P. D. Sun, S. Ugolini, and E. Vivier. 2005. "Recognition of peptide-MHC class I complexes by activating killer immunoglobulin -like receptors." Proc Natl Acad Sci U S A no. 102 (37):13224-9. doi: 10.1073/pnas.0503594102.
[72]
Tajik, N., F . Shahsavar, H. Poormoghim, M. F. Radjabzadeh, T. Mousavi, and A. Jalali. 2011. "KIR3DL1+HLA-B Bw4Ile80 and KIR2DS1+HLA -C2 combinations are both associated with ankylosing March 2016 spondylitis in the Iranian population." Int J Immunogenet no. 38 (5):403 -9. doi: 10. 1111/j.1744- 313X.2011.01024.x.
[73]
Takeshita, Louise Y. C., Faviel F. Gonzalez-Galarza, Eduardo J. M. dos Santos, Maria Helena T. Maia, Mushome M. Rahman, Syed M. S. Zain, Derek Middleton, and Andrew R. Jones. 2013. "A database for curating the associations be tween killer cell immunoglobulin -like receptors and diseases in worldwide populations." Database: The Journal of Biological Databases and Curation no. 2013:bat021. doi: 10.1093/database/bat021.
[74]
Terunuma, H., X. Deng, Z. Dewan, S. Fujimoto, and N. Yamamoto. 2008. "Potential role of NK cells in the induction of immune responses: implications for NK cell -based immunotherapy for cancers and viral infections." Int Rev Immunol no. 27 (3):93-110. doi: 10.1080/08830180801911743.
[75]
Thananchai, H., G. Gillespie, M. P. Martin, A. Bashirova, N. Yawata, M. Yawata, P. Easterbrook, D. W. McVicar, K. Maenaka, P. Parham, M. Carrington, T. Dong, and S. Rowland -Jones. 2007. "Cutting Edge: Allele -specific and peptide -dependent interactions between KIR3DL1 and HLA -A and HLA -B." J Immunol no. 178 (1):33-7.
[76]
Thomas, G. P., and M. A. Brown. 2010. "Genetics and genomics of ankylosing spondylitis." Immunol Rev no. 233 (1):162-80. doi: 10.1111/j.0105-2896.2009.00852.x.
[77]
Tsui, F. W., H. W. Tsui, A. Akram, N. Haroon, and R. D. Inman. 2014. "The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis." Appl Clin Genet no. 7:105 -15. doi: 10.2147/tacg.s37325.
[78]
Vendelbosch, S., S. C. Heslinga, M. John, K. van Leeuwen, J. Geissler, M. de Boer, M. W. Tanck, T. K. van den Berg, J. B. Crusius, I. E. van der Horst-Bruinsma, and T. W. Kuijpers. 2015. "Study on the Protective Effect of the KIR3DL1 Gene in Ankylosing Spondylitis." Arthritis Rheumatol no. 67 (11):2957 -
[65]
doi: 10.1002/art.39288.
[79]
Vilches, C., and P. Parham. 2002. "KIR : diverse, rapidly evolving receptors of innate and adaptive immunity." Annu Rev Immunol no. 20:217-51. doi: 10.1146/annurev.immunol.20.092501.134942.
[80]
Vivier, E., J. A. Nunes, and F. Vely. 2004. "Natural killer cell signaling pathways." Science no. 306 (5701):1517-9. doi: 10.1126/science.1103478.
[81]
Vivier, Eric, David H. Raulet, Alessandro Moretta, Michael A. Caligiuri, Laurence Zitvogel, Lewis L. Lanier, Wayne M. Yokoyama, and Sophie Ugolini. 2011. "Innate or Adaptive Immunity? The Example of Natural Killer Cells." Science (New York, N.Y.) no. 331 (6013):44-49. doi: 10.1126/science.1198687.
[82]
Walzer, T., M. Blery, J. Chaix, N. Fuseri, L. Chasson, S. H. Robbins, S. Jaeger, P. Andre, L. Gauthier, L. Daniel, K. Chemin, Y. Morel, M. Dalod, J. Imbert, M. Pierres, A. Moretta, F. Romagne, and E. Vivier. 2007. "Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46." Proc Natl Acad Sci U S A no. 104 (9):3384-9. doi: 10.1073/pnas.0609692104.
[83]
Walzer, T., M. Dalod, S. H. Robbins, L. Zitvogel, and E. Vivier. 2005. "Natural-killer cells and dendritic cells: "l'union fait la force"." Blood no. 106 (7):2252-8. doi: 10.1182/blood-2005-03-1154.
[84]
Wang, S., G. Li, R. Ge, Z. Duan, Z. Zeng, T. Zhang, J. Gao, T. Yang, S. Liu, S. Wu, D. Fan, S. Xu, J. Xu, L. Zhang, Z. Shuai, D. Ye, Y. Zou, and F. Pan. 2013. "Association of KIR genotype with susceptibility to HLA-B27-positive ankylosing spondylitis." Mod Rheumatol no. 23 (3):538-41. doi: 10.1007/s10165-012- 0692-z.
[85]
Wende, H., M. Colonna, A. Ziegler, and A. V olz. 1999. "Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4." Mamm Genome no. 10 (2):154 -60.
[86]
Wilson, M. J., M. Torkar, A. Haude, S. Milne, T. Jones, D. Sheer, S. Beck, and J. Trowsdale. 2000. "Plasticity in the organization and sequences of human KIR/ILT gene families." Proc Natl Acad Sci U S A no. 97 (9):4778-83. doi: 10.1073/pnas.080588597.
[87]
Wong-Baeza, I., A. Ridley, J. Shaw, H. Hatano, O. Rysnik, K. McHugh, C. Piper, S. Brackenbridge, R. Fernandes, A. Chan, P. Bowness, an d S. Kollnberger. 2013. "KIR3DL2 binds to HLA -B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis." J Immunol no. 190 (7):3216-24. doi: 10.4049/jimmunol.1202926.
[88]
Zochling, J., and E. U. Smith. 2010. "Seronegative spondyloarthritis." Best Pract Res Clin Rheumatol no. 24 (6):747-56.
[89]
Zvyagin, I. V., I. Z. Mamedov, O. V. Britanova, D. B. Staroverov, E. L. Nasonov, A. G. Bochkova, A. V. Chkalina, A. A. Kotlobay, D. O. Korostin, D. V. R ebrikov, S. Lukyanov, Y. B. Lebedev, and D. M. Chudakov. 2010. "Contribution of functional KIR3DL1 to ankylosing spondylitis." Cell Mol Immunol no. 7 (6):471-6. doi: 10.1038/cmi.2010.42.